News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2012

Epigenomics AG: Study Shows Patient Preference for Blood Based Colorectal Cancer Screening

06.03.2012 | 120306_Epigenomics_Press_release_ASPO Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that results of a survey on colorectal cancer (CRC) screening preferences conducted by Jennifer Taber et al. (Department of Psychology University of Utah, Huntsman Cancer Institute, ARUP Laboratories) were presented at […]

Read more

Epigenomics Septin9 Biomarker detects Colon Cancer equally in both sides of the Colon

16.02.2012 | 120216_Epigenomics_Press_release_Septin9 Berlin, Germany, and Seattle, WA, U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, is pleased to announce the results from a study conducted in collaboration with Professor Dr. Béla Molnár and his team from the 2nd Department of Internal Medicine of Semmelweis University in Budapest, Hungary. […]

Read more

Epigenomics’ Epi proLung® BL Assay shows Strong Performance as Confirmation Test for Lung Cancer Diagnosis

14.02.2012 | 120214_Epigenomics_Press_release_SHOX2 Berlin, Germany, and Seattle, WA, U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, is pleased to announce the results from a clinical study conducted by Professor Dr. Manfred Dietel and his team from the Institute of Pathology of the Charité University Hospital in Berlin, Germany. In […]

Read more

Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer

05.01.2012 | 120105_Press_release_Epigenomics_AG_TFAP_Prof._Ebert Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, is pleased to announce the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in the January edition of The New England […]

Read more

Epigenomics announces initiation of PMA filing for Epi proColon, provides update on regulatory timeline

04.01.2012 | 2012-01-04_Press_release_Epigenomics_initiation_PMA_filing Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, is pleased to announce that it has submitted the first module of its premarket approval (PMA) submission to the US Food and Drug Administration (FDA) on December 30, 2011.

Read more